

Tabla Suplementaria 1. Estudios excluidos y motivo de exclusión.

<b>Estudio</b>	<b>Razón de exclusión</b>
Alberici, F(1)	Datos de neuropatía faltantes o no especificados
Aldea, JJ(2)	Revisión narrativa, no revisión sistemática
Blaes, F(3)	Revisión narrativa, no revisión sistemática
Braun-Moscovici, Y(4)	Datos de neuropatía faltantes o no especificados
Butterly, Sj(5)	Datos de neuropatía faltantes o no especificados
Charles, P(6)	Datos de neuropatía faltantes o no especificados
Choudhry, M(7)	Caso clínico
Da Silca, LS(8)	Datos de neuropatía faltantes o no especificados
Eriksson, P(9)	Datos de neuropatía faltantes o no especificados
Gorson, KC(10)	Tipo de neuropatía no especificado
Gottenberg, JE(11)	Tipo de neuropatía no especificado
Kelly, JJ (12)	Caso clínico
Moog, P (13)	Caso clínico
Piccione, E(14)	Eficacia de RTX no evaluado
Zenone, T(15)	Datos de neuropatía faltantes o no especificados
Zhang, W (16)	Eficacia de RTX no evaluado
Perna (17)	Revisión narrativa, no revisión sistemática
Ghinoi, A(18)	Revisión narrativa, no revisión sistemática
Puechal, X(19)	Revisión narrativa, no revisión sistemática
Noronha, V (20)	Revisión narrativa, no revisión sistemática
Nobile-orazio, E(21)	Revisión narrativa, no revisión sistemática
Gwathmey, KG(22)	Revisión narrativa, no revisión sistemática
Holle, JU (23)	Revisión narrativa, no revisión sistemática
Bril, V (24)	Revisión narrativa, no revisión sistemática
Bosch, X (25)	Datos de neuropatía faltantes o no especificados

RTX: Rituximab

1. Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. *Rheumatology (United Kingdom)*. 2015;54(7):1153-60.
2. Aldea JJ. [Monoclonal antibodies in inflammatory disease of the muscle and peripheral nervous system]. *Neurologia*. 2012;27(1):39-45.
3. Blaes F. Diagnosis and therapeutic options for peripheral vasculitic neuropathy. *Ther Adv Musculoskelet Dis*. 2015;7(2):45-55.
4. Braun-Moscovici Y, Butbul-Aviel Y, Guralnik L, Toledano K, Markovits D, Rozin A, et al. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. *Rheumatol Int*. 2013;33(6):1495-504.

5. Butterly SJ, Pillans P, Horn B, Miles R, Sturtevant J. Off-label use of rituximab in a tertiary Queensland hospital: ORIGINAL ARTICLE. Internal Medicine Journal. 2010;40(6):443-52.
6. Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: A multicentre retrospective study on 80 patients. Rheumatology (United Kingdom). 2014;53(3):532-9.
7. Choudhry M, Rao N, Juneja R. Successful treatment of cryoglobulinaemia with rituximab. Case Rep Nephrol Urol. 2012;2(1):72-7.
8. da Silva LS, de Campos KVM, de Melo AKG, de Brito DCSE, Braz AS, Medeiros Freire EA. Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: Report of seven cases and literature review. Revista Brasileira de Reumatologia. 2015;55(6):531-5.
9. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med. 2005;257(6):540-8.
10. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007;35(1):66-9.
11. Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: Results in 78 patients of the AutoImmune and Rituximab registry. Annals of the Rheumatic Diseases. 2013;72(6):1026-31.
12. Kelly JJ. Chronic peripheral neuropathy responsive to rituximab. Rev Neurol Dis. 2006;3(2):78-81.
13. Moog P, Thuermel K. Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives. Ther Clin Risk Manag. 2015;11:1749-58.
14. Piccione E, Salame K, Katirji B. Vasculitic neuropathy associated with concomitant active hepatitis C and B. Neurology. 2013;80(1).
15. Zenone T. Flare of essential mixed cryoglobulinemic vasculitis with hemorrhagic bullous purpura after rituximab infusion. International Journal of Rheumatic Diseases. 2013;16(2):237-9.
16. Zhang W, Zhou G, Shi Q, Zhang X, Zeng XF, Zhang FC. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clinical and Experimental Rheumatology. 2009;27(1 SUPPL. 52):S65-S9.
17. Perna P, Cioffi R, Merchionda A, Moscato P, Raimo S, Caputo D. Mixed cryoglobulinemia treated with rituximab. Italian Journal of Medicine. 2013;7:94.
18. Ghinoi A, Mascia MT, Puccini R, Ferri C. [Autoimmune and lymphoproliferative HCV-correlated manifestations: example of mixed cryoglobulinaemia (review)]. G Ital Nefrol. 2004;21(3):225-37.
19. Puéchal X, Guillemin L. Therapeutic immunomodulation in systemic vasculitis: Taking stock. Joint Bone Spine. 2013;80(4):374-9.
20. Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia. J Clin Oncol. 24. United States2006. p. e3.
21. Nobile-Orazio E. Treatment of dys-immune neuropathies. J Neurol. 2005;252(4):385-95.
22. Gwathmey KG, Burns TM, Collins MP, Dyck PJ. Vasculitic neuropathies. Lancet Neurol. 2014;13(1):67-82.
23. Holle JU, Laudien M, Gross WL. Clinical Manifestations and Treatment of Wegener's Granulomatosis. Rheumatic Disease Clinics of North America. 2010;36(3):507-26.
24. Bril V, Katzberg HD. Acquired immune axonal neuropathies. Continuum (Minneapolis Minn). 2014;20(5 Peripheral Nervous System Disorders):1261-73.
25. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: A systematic review. Journal of the American Medical Association. 2007;298(6):655-69.

